Table 2.
Comparison of anti-SARS-CoV-2 IgG antibody responses between adolescents with T1D and healthy controls regardless of pre-vaccination SARS-CoV-2 IgM and IgG test results
| Variables | Adolescents with T1D [n = 120 (81 + 39)] | Healthy controls [n = 59 (40 + 19)] | P value |
|---|---|---|---|
| T1 (days) median (25th, 75th percentiles) | 28 (28, 31) | 28 (28, 30) | 0.144 |
| T2 (days) median (25th, 75th percentiles) | 31 (29, 33) | 31 (29, 31) | 0.342 |
| Anti-SARS-CoV-2 IgG titer ≥50 AU/ml at T1, n (%) | 120 (100%) | 59 (100%) | − |
| Anti-SARS-CoV-2 IgG titer ≥1,050 AU/ml at T1, n (%) | 98 (81.7%) | 51 (86.4%) | 0.421 |
| Anti-SARS-CoV-2 IgG titer in AU/ml at T1 median (25th, 75th percentiles) | 2,460.55 (1,318.53, 25,385.8) | 3,603.60 (1,538.80, 24,276.70) | 0.260 |
| Anti-SARS-CoV-2 IgG titer ≥1,050 AU/ml at T2, n (%) | 120 (100%) | 59 (100%) | − |
| Anti-SARS-CoV-2 IgG titer in AU/ml at T2 median (25th, 75th percentiles) | 22,695.4 (13,565.87, 36,815.85) | 25,366.0 (17,253.1, 42,008.0) | 0.193 |
T1, days from first vaccine dose to anti-SARS-CoV-2 IgG measurement; T2, days from second vaccine dose to anti-SARS-CoV-2 IgG measurement, T1D, type 1 diabetes, AU, arbitrary unit.